Skip to content

Compassionate Access of the Miltenyi Device for CD34+ Cell Selection

Compassionate Access of the Miltenyi Device for CD34+ Cell Selection

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02438904
Enrollment
200
Registered
2015-05-08
Start date
2015-05-06
Completion date
2027-05-01
Last updated
2026-05-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Blood And Marrow Transplantation

Keywords

Blood And Marrow Transplantation, Stem cell transplantation, SCT, Poor graft function, CD34+ cell infusion

Brief summary

Objectives: Primary Objective To provide compassionate access to the Miltenyi device for CD34+ cell infusions to patients who experience poor graft function after stem cell transplantation (SCT).

Detailed description

The therapy that you will receive involves you being given an infusion of CD34 positive stem cells. Below is a detailed explanation of the therapeutic procedures that will be performed. CD34 positive stem cells infusion: The CD34 positive stem cells are collected from a donor's blood. The blood cells go through CD34 (stem cell) selection process that collects the stem cells that are needed for the infusion. This process collects the early immune cells your body will need to regrow your immune system, and makes sure that other cells will not be infused. This process will decrease (but not eliminate completely) the other types of cells. If you agree to receive this treatment, the CD34 cells will then be infused into your body. The CD34 positive cells will be given by vein in either an inpatient or outpatient treatment area. The infusion will last about 10-30 minutes. Before the infusion, you will receive Tylenol (acetaminophen) by mouth and Benadryl (diphenhydramine hydrochloride) by mouth or vein about 30-60 minutes before the infusion. These drugs will be used to help lower the risk of side effects. If side effects occur during the infusion, the doses of the drugs may be adjusted (up or down) until the symptoms are gone. Also, if you have side effects during the infusion, you will be observed for 2 hours after it is given or until the symptoms have stopped completely (whichever is later). During this time, your blood pressure, heart rate, breathing rate, temperature, and the level of oxygen in your blood will be checked every 15-30 minutes. About 4-6 weeks after the first infusion, you may receive an additional infusion, if your doctor thinks it is needed. Clinic Visits: One (1) time a week after the infusion, until your doctor thinks it is no longer clinically needed, you will have the following tests: * Blood (about 1 teaspoon) will be drawn for routine tests. * You will be checked for signs of graft versus host disease (GVHD). Symptoms of GVHD include skin rash, nausea, vomiting, diarrhea, and abnormal liver function. This is an investigational study. The CD34 positive stem cell infusion to help boost cell counts is not FDA approved. Up to 75 patients will be enrolled on this treatment.

Interventions

BIOLOGICALCD34 Positive Stem Cell Infusion

Participants infused by vein with around 1 - 4 million/kg CD34+ selected cells.

DEVICEMiltenyi device

Miltenyi device is used for CD34+ cell infusions) to patients who experience poor graft function after stem cell transplantation (SCT).

Sponsors

M.D. Anderson Cancer Center
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

1\) Patients who have poor or no graft function post stem cell transplantation.

Exclusion criteria

N/A

Design outcomes

Primary

MeasureTime frameDescription
Increased Graft Function after Stem Cell Transplantation (SCT)4 weeksBlood drawn for signs of graft versus host disease (GVHD).

Countries

United States

Contacts

CONTACTElizabeth Shpall, MD
eshpall@mdanderson.org713-745-2161
PRINCIPAL_INVESTIGATORElizabeth Shpall, MD

M.D. Anderson Cancer Center

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 21, 2026